July 18 (Reuters) - Progenics Pharmaceuticals Inc PGNX.O
* Progenics Pharmaceuticals - On July 14 received notification of a Paragraph IV certification for certain patents for subcutaneous Relistor
* Progenics Pharma - Certification resulted from filing by par sterile products of ANDA challenging patents for subcutaneous relistor - SEC Filing
* Progenics Pharma - Co, licensee for relistor, Salix Pharmaceuticals, assessing notification, intend to "vigorously" enforce relistor intellectual property rights